In advanced HCC, the combination of the anti-vascular endothelial growth factors antibody bevacizumab and the anti-programmed death ligand-1 (PD-L1) antibody atezolizumab has established a new first-line benchmark for reaching a median OS duration of 19 months, thus representing a breakthrough in the management of HCC (5). This evidence concerns the gene CD274 and hepatocellular carcinoma.